COVID-19 is a disease defined by symptoms and is not a virus. It’s therefore not transmitted nor can you test for it using nasal or throat testing kits. SARS-CoV-2 is the coronavirus that prompted the worldwide pandemic response.
We report broad serological profiles within the cohort, detecting antibody binding to other human coronaviruses. 202(>99%) participants had SARS-CoV-2 specific antibodies, with SARS-CoV-2 neutralization and spike-ACE2 receptor interaction blocking observed in 193(95%) individuals. A significant positive correlation (r=0.7804) between spike-ACE2 blocking antibody titers and neutralization potency was observed. Further, SARS-CoV-2 specific CD8+ T-cell responses were clear and quantifiable in 95 of 106(90%) HLA-A2+ individuals.
Conclusions: This lack of clear benefit should cause governments to rethink their vaccination policy.
The present assessment raises the question whether it would be necessary to rethink policies and use COVID-19 vaccines more sparingly and with some discretion only in those that are willing to accept the risk because they feel more at risk from the true infection than the mock infection. Perhaps it might be necessary to dampen the enthusiasm by sober facts? In our view, the EMA and national authorities should instigate a safety review into the safety database of COVID-19 vaccines and governments should carefully consider their policies in light of these data. Ideally, independent scientists should carry out thorough case reviews of the very severe cases, so that there can be evidence-based recommendations on who is likely to benefit from a SARS-CoV2 vaccination and who is in danger of suffering from side effects. Currently, our estimates show that we have to accept four fatal and 16 serious side effects per 100,000 vaccinations in order to save the lives of 2–11 individuals per 100,000 vaccinations, placing risks and benefits on the same order of magnitude.
SARS-CoV-2 spike antigen-specific IgG and IgA elicited by infection mediate viral neutralization and are likely an important component of natural immunity, however, limited information exists on vaccine induced responses. We measured COVID-19 mRNA vaccine induced IgG and IgA in serum serially, up to 145 days post vaccination in 4 subjects. Spike antigen-specific IgG levels rose exponentially and plateaued 21 days after the initial vaccine dose. After the second vaccine dose IgG levels increased further, reaching a maximum approximately 7–10 days later, and remained elevated (average of 58% peak levels) during the additional >100 day follow up period. COVID-19 mRNA vaccination elicited spike antigen-specific IgA with similar kinetics of induction and time to peak levels, but more rapid decline in serum levels following both the 1st and 2nd vaccine doses (<18% peak levels within 100 days of the 2nd shot). The data demonstrate COVID-19 mRNA vaccines effectively induce spike antigen specific IgG and IgA and highlight marked differences in their persistence in serum.
Nanobiotechnology is emerging very promising to investigate novel methodologies for managing COVID-19 pandemic/endemic successfully. In this direction, experts have explored the opto-electro-magnetic nanosystem to detect the SARS-CoV-2 virus using a biosensing approach. Such optical, electrical, or magnetic biosensors function based on geno-sensing and immune-sensing has detected the SARS-CoV-2 virus selectively at a very low level. These efficient-miniaturized biosensors can be operated using a smartphone and promoted for clinical application for early-stage diagnostics of COVID-19 infection. The successful integration of these SARS-CoV-2 virus sensors with AI and IoMT enables virus detection at point-of-location and sharing of bioinformatics with the medical center at the same time for timely therapeutics decision. This approach is also useful for tracking tasks and managing COVID-19 infection according to patient infection profiling. To avoid human-to-human SARS-CoV-2 virus transmission, experts have developed stimuli-responsive nanotechnology enable which can not only trap aerosol of virus size but can eradicate viruses on applying external stimulation for example nanoenable photo-sensitive virus degradation. Various types of clothes containing nanoparticles have demonstrated SARS-CoV-2 virus trapping and eradication successfully [2,9]. However, significant attention is required to increase the production and distribution of these masks for public use.
Manufacturers have been granted exemption from liability for any resulting harm. Ruud Dobber, a member of AstraZeneca’s senior executive team, said: “This is a unique situation where we as a company simply cannot take the risk if in … four years the vaccine is showing side effects.” (The government has taken on the liability and has an insurance scheme in place.)
So it is curious that since the Covid pandemic began, this hugely influential figure has been at the heart of the scientific establishment’s efforts to stifle debate on the origins of the virus that emerged in Wuhan.
The Oxford, Edinburgh and London-educated infectious diseases expert has claimed scientists ‘know’ Covid was not created in a lab, suggested such an idea was a ‘conspiracy theory’ and insisted that ‘evidence’ indicates it spilled over naturally from animals.
Now, The Mail on Sunday can reveal that emails from America’s top infectious disease chief, Anthony Fauci, show how Farrar played a key role behind the scenes in marshalling top scientists’ response to concerns over the virus’s origins, even demanding secrecy on their discussions.
Crucially, he was a central figure behind two landmark statements published by leading science journals that helped to silence dissident views, arguing against the plausibility of ‘any type of laboratory-based scenario’.
Dr. Peter McCullough has been the world’s most prominent and vocal advocate for early outpatient treatment of SARS-CoV-2 (COVID-19) infection in order to prevent hospitalization and death. On May 19, 2021, I interviewed him about his efforts as a treating physician and researcher. From his unique vantage point, he has observed and documented a profoundly disturbing policy response to the pandemic—a policy response that may prove to be the greatest malpractice and malfeasance in the history of medicine and public health.”
Link to interview audio format released by Julian Charles of The Mind Renewed podcast.
The concern that SARS-CoV-2 could be spread by people without symptoms originally came from a single case report. It was alleged that an asymptomatic woman from China had spread the virus to 16 other contacts in Germany. Later reports showed that, at the time of contact, this woman was taking medication for flu-like symptoms, invalidating the evidence provided for the theory of asymptomatic transmission. As with other common respiratory viruses, SARS-CoV-2 spreads by being exhaled, coughed or sneezed into the air. The largest droplets fall quickly and settle on the ground whilst the most lightweight particles, known as aerosols, may remain suspended in the air for days. Once the virus is present in the environment, it spreads by finding its way into the respiratory tract of new hosts in a large enough quantity (known as the ‘viral load’ or ‘infectious dose’) to infect them. The theory of fomite transmission (touching contaminated surfaces and then touching the face) is not supported by scientific evidence.
…In asymptomatic individuals, the viral load is typically very low and the infectious period is also short in duration. They may still exhale virus particles, which another person may encounter. However, the overall likelihood of transmitting the disease to others is negligible. Thus asymptomatic cases are not the major drivers of epidemics. As Dr Anthony Fauci of the US National Institute of Allergy and Infectious Diseases stated in March 2020: ‘In all the history of respiratory-borne viruses of any type, asymptomatic transmission has never been the driver of outbreaks. The driver of outbreaks is always a symptomatic person.’
No evidence that masks reduce viral transmission in real-world settings
Wearing masks is likely to do harm
Masks increase compliance with the ongoing public health tyranny
Masks are dehumanising
Masks perpetuate the elevated levels of fear
The recently-launched Smile Free campaign – of which I’m a part – is campaigning for the removal of mask mandates in the UK, and believes that, in a democratic society, the evidential bar to justify mandating a behaviour should be set very high. The research in support of masks offering protection against SARS-CoV-2 infection falls a long way short of this threshold, and the negative consequences of wearing them are considerable. The decision whether to wear a face covering should be a personal one, not one imposed by Government diktat. All mask mandates must be lifted on June 21 and this most insidious of all the Covid-19 restrictions must never return.
Scientists from the Cleveland Clinic, USA, have recently evaluated the effectiveness of coronavirus disease 2019 COVID-19) vaccination among individuals with or without a history of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
The study findings reveal that individuals with previous SARS-CoV-2 infection do not get additional benefits from vaccination, indicating that COVID-19 vaccines should be prioritized to individuals without prior infection. The study is currently available on the medRxiv* preprint server.
Science journals have encouraged and enforced a false Covid narrative
Bear in mind that in the heat of this pandemic, papers printed in important journals were peer-reviewed within 10 weeks; one rattled through the process in just nine days for Nature. But, like Petrovsky, I have heard similar stories from many other frustrated experts who confronted the conventional wisdom that this lethal virus was a natural spillover event. Some could not even get letters published, let alone challenge those key papers promoting the Chinese perspective which have since turned out to be flawed or wrong.
Only now is acceptance emerging that the science establishment colluded to dismiss the lab leak hypothesis as a conspiracy theory, assisted by prominent experts with clear conflicts of interest, patsy politicians and a pathetic media that mostly failed to do its job. And yet, at the heart of this scandal lie some of the world’s most influential science journals. These should provide a forum for pulsating debate as experts explore and test theories, especially on something as contentious and fascinating as the possible origins of a global pandemic. Instead, some have played a central role in shutting down discussion and discrediting alternative views on the origins, with disastrous consequences for our understanding of events.
This is the first instalment of my three-part investigative report on the Chinese-made Innova lateral flow test. Vast sums of UK taxpayers’ money have been paid to a California start-up for tests that have failed to stand up to scrutiny.
…Innova Medical Group, the company benefiting from the UK Government’s huge testing contract, is owned by the private equity group Pasaca Capital which was founded by a Chinese investment banker, the enigmatic Dr Charles Huang, in 2017. It has been revealed to be the single largest recipient of the Department of Health’s Covid contracts after signing a £496million deal to supply LFTs last year. An earlier contract with Innova cost the taxpayer £107million.
Conclusions Individuals who have had SARS-CoV-2 infection are unlikely to benefit from COVID-19 vaccination, and vaccines can be safely prioritized to those who have not been infected before.
A Biological Safety Level (BSL 1, 2, 3, or 4) is assigned to a biological lab as a safeguard to protect laboratory personnel, as well as the surrounding environment and community.
With research into potential treatments, therapies and vaccines for the SARS-CoV-2 virus (known widely as the COVID-19 Coronavirus) exploding across the globe, many institutions and laboratories are wondering whether their equipment and lab are considered safe to contain samples of the virus. As discussed in our previous blog on biosafety levels, airborne transmissible diseases like COVID-19 are typically categorized as Biosafety Level 3 (BSL-3). BSL-3 laboratories are almost always purpose-constructed containment laboratories, outfitted with specialized equipment and HVAC systems designed to ensure no airborne particles can exit the contained space.
Dr Bauer of the Francis Crick Institute explains that the Pfizer vaccine produces 5-6 times fewer neutralising antibodies that play a key role in protecting us from the Indian variant. He suggests that booster Pfizer jabs will be essential.
Levels of antibodies in the blood of vaccinated people that are able to recognise and fight the new SARS-CoV-2 Delta variant first discovered in India (B.1.617.2) are on average lower than those against previously circulating variants in the UK, according to new laboratory data from the Francis Crick Institute and the National Institute for Health Research (NIHR) UCLH Biomedical Research Centre, published today (Thursday) as a Research letter in The Lancet.
The results also show that levels of these antibodies are lower with increasing age and that levels decline over time, providing additional evidence in support of plans to deliver a vaccination boost to vulnerable people in the Autumn.
In the case of single-dose recipients, our data show that NAbTs are significantly lower against B.1.617.2 and B.1.351 VOCs relative to B.1.1.7, implying that although a single dose might still afford considerably more protection than no vaccination, single-dose recipients are likely to be less protected against these SARS-CoV-2 variants. These data therefore suggest that the benefits of delaying the second dose, in terms of wider population coverage and increased individual NAbTs after the second dose,7 must now be weighed against decreased efficacy in the short-term, in the context of the spread of B.1.617.2. Worldwide, our data highlight the ongoing need to increase vaccine supply to allow all countries to extend second-dose protection as quickly as possible.
In the longer term, we note that both increased age and time since the second dose of BNT162b2 significantly correlate with decreased NAb activity against B.1.617.2 and B.1.351—both of which are also characteristic of the population in the UK at highest risk of severe COVID-19 (ie, older and vaccinated earlier), independent of other existing factors such as compromised immune status or comorbidity, or geographic-specific responses to vaccination.
SARS-Cov-2 is a more stable virus than influenza. Trillions of replications have thrown up a handful of variants of concern, clustering around a small set of mutations. These variants are worth monitoring but the vaccines effectively prevent them causing serious illness. There is a theoretical risk of a more dangerous variant but it does not seem more likely than a shift in the influenza virus. If it were to occur, we could now manage it with short-term measures and rapid vaccine modification.
…Vaccination protects the vaccinated. It helps protect others but it means that we take no greater risk in the autumn of 2020 than in the autumn of 2019. Interventions should be proportionate to that – which means that most cannot be justified.
Some are worth retaining, like improved hygiene in public places or greater readiness to stay at home with respiratory symptoms. It is probably a good idea to invest further in the search for effective antiviral therapies. Promoting better population health through diet and exercise is always a good thing. But it is time for a bonfire of face masks and the despatch of lateral flow tests to landfill.
People who recover from mild COVID-19 have bone-marrow cells that can churn out antibodies for decades, although viral variants could dampen some of the protection they offer.
Many people who have been infected with SARS-CoV-2 will probably make antibodies against the virus for most of their lives. So suggest researchers who have identified long-lived antibody-producing cells in the bone marrow of people who have recovered from COVID-19.
Citizens subjected to punitive restrictions on their liberties and movement for more than 12 months, are now being forced into mass, and what will soon be, mandatory vaccination programs to gain back their freedoms. Political leaders continue use the vacuous and dishonest slogan of “following the science” that many still believe, but are they leading us into another form of hell?
The Covid-19 vaccines are new vaccines and only provisionally approved. They are still in the trial phase which ends at earliest in 2023. Brilliant they may well be, and enormously enriching for their investors, but are our Government’s providing the facts for informed choice in vaccination? Are there other risks to their rushed vaccine rollouts, including to front line medical and essential service workers? And why are so many eminent scientists and influential community leaders in our countries being silenced by social and mainstream media?
The Victorian Government recently commissioned a paper entitled Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. We are not hopeful but will attempt to discuss the paper with one of its authors in another episode.
In the meantime, to talk about mRNA vaccines and Antibody Dependent Enhancement is Professor Dolores Cahill, a renown expert in immunology and the study of immune systems.
Dr. Cahill is a Professor of University College Dublin and was Group Leader of the Max-Planck-Institute in Berlin, Germany from 1995 to 2003. She is an Inventor, Founder and Shareholder of companies and has international Patents with applications for improving the early diagnosis of diseases such as auto immune diseases & cancer.
Dr. Cahill has been an Expert in the EU for some 15 years in Future & Emerging technologies. Professor Cahill’s latest business ventures include the World Freedom Alliance, a worldwide platform of organisations offering access to justice, true dialogue for health science and politics, holding worldwide officials to account under the law. The World Freedom Alliance offers transparent evidence-based solutions and encourages robust debate with media, scientists and governments to ensure fundamental freedoms for people of the world.
Traffic log cookies are used to measure site traffic. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT
Privacy & Cookies Policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.